Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: FAK/VEGFR3 inhibitors - CureFAKtor Pharmaceuticals

Next Previous
Drug Profile

Research programme: FAK/VEGFR3 inhibitors - CureFAKtor Pharmaceuticals

Alternative Names: C10; C9; C9A; CFAK-C10; CFAK-C4; CFAK-C9; CFAK-C9a; CFAK-Y15; Chloropyramine; Chloropyramine hydrochloride; FAK inhibitors - CureFAKtor; FAK technology platform - CureFAKtor; Y15

Latest Information Update: 24 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureFAKtor Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Focal adhesion protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pancreatic cancer; Solid tumours

Most Recent Events

  • 24 Oct 2024 Discontinued - Preclinical for Solid tumours in USA (PO)
  • 03 May 2016 No recent reports on development identified - Preclinical for Solid tumours and Pancreatic cancer in USA (PO)
  • 01 May 2016 Discontinued - Preclinical for Pancreatic cancer in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top